$Cassava Sciences (SAVA.US)$Bullishš Cassava Sciences Annou...
$Cassava Sciences(SAVA.US$Bullishš Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimerās Disease Dec 06, 2022. To ensure the highest integrity of data analysis, outside biostatisticians with specific expertise in Alzheimerās disease will conduct an independent statistical analysis on the clinical dataset. Cassava Sciences may announce study results approximately year-end 2022, pending completion of a study report by outside biostatisticians.
āWe are thrilled with the progress made to date in the clinical development of simufilam, our oral drug candidate for people with Alzheimerās disease,ā said Remi Barbier, President & CEO. āWe applaud recent clinical advances with anti-amyloid antibody drugs for Alzheimerās, but these may not be enough. I think innovations are needed around new targets, new molecules, drug safety and dosing. I believe Cassava Sciences may be at the forefront of this effort to innovate.ā
āWe are thrilled with the progress made to date in the clinical development of simufilam, our oral drug candidate for people with Alzheimerās disease,ā said Remi Barbier, President & CEO. āWe applaud recent clinical advances with anti-amyloid antibody drugs for Alzheimerās, but these may not be enough. I think innovations are needed around new targets, new molecules, drug safety and dosing. I believe Cassava Sciences may be at the forefront of this effort to innovate.ā
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
